Systemic Therapy for Hereditary Breast Cancers.
Date
2023-02-01Author
Harvey-Jones, EJ
Lord, CJ
Tutt, ANJ
Type
Journal Article
Metadata
Show full item recordAbstract
Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment for such breast cancers, including approved chemotherapeutic approaches and also targeted treatment approaches using poly-(ADP ribose) polymerase inhibitors. We also discuss experimental approaches to treating hereditary breast cancer, including new small molecule DNA repair inhibitors and also immunomodulatory agents. Finally, we discuss how drug resistance emerges in patients with hereditary breast cancer, how this might be delayed or prevented, and how biomarker-adapted treatment is molding the future management of hereditary breast cancer.
Collections
Subject
Biomarkers
Chemotherapy
Drug resistance
Hereditary breast cancer
PARPi
Humans
Female
Breast Neoplasms
Genes, BRCA2
Poly(ADP-ribose) Polymerase Inhibitors
DNA Repair
Research team
Directorate Breast Canc
Language
eng
License start date
2023-02-01
Citation
Hematology / Oncology Clinics of North America, 2023, 37 (1), pp. 203 - 224
Publisher
W B SAUNDERS CO-ELSEVIER INC